| Literature DB >> 17226221 |
C R Hutchinson1, C W Borell, M J Donovan, F Kato, H Motamedi, H Nakayama, R L Rubin, S L Streicher, R G Summers, E Wendt-Pienkowski, W L Wessel.
Abstract
The possibilities for the design of new drug screening and development strategies directed to a specific objective on the basis of genetic engineering of microorganisms is discussed from two points of view. Firstly, results of work on genetic hybrids of STREPTOMYCES species for the production of new metabolites such as mederrhodin (1) and aloespanoarin II (4) are described. Secondly, the enhanced production of known metabolites such as tetracenomycin A (2) (11) and tetracenomycin C (9) by recombinant STREPTOMYCES species is considered. Mechanistic aspects of polyketide metabolism are included.Entities:
Year: 1991 PMID: 17226221 DOI: 10.1055/s-2006-960227
Source DB: PubMed Journal: Planta Med ISSN: 0032-0943 Impact factor: 3.352